





First Judicial District of PA: Trial Division - Civil

Mass Tort Program



First Judicial District of PA: Trial Division – Civil

MASS TORT PROGRAM
PENDING BREAKDOWN 2019



Program:	Inventory Pending	% of Inventory
Risperdal	6,912	64.48%
Xarelto	1,978	18.45%
Vena Cava Filter	842	7.86%
Asbestos	562	5.24%
Essure	288	2.69%
Pelvic Mesh Litigation	81	0.76%
Reglan Litigation	52	0.49%
Phen Fen	1	0.01%
Firefighter Hearing Loss	1	0.01%
Paxil Birth Defect	1	0.01%
Yaz/Yasmin/Ocella Litigation	1	0.01%
TOTAL	10,719	100%


** Other includes Phen Fen (1), Yaz/Yasmin/Ocella Litigation (1), Paxil Birth Defect Litigation (1) and Firefighter Hearing Loss (1).*

First Judicial District of PA: Trial Division - Civil


**MASS TORT REPORT
YEAR TO DATE DECEMBER TERM 2019**

	Records Pending 01/07/19	Filings	Re-Open Records	Total Records Disposed	Net Deferred	Net Transfer	Records Pending 01/05/20	Deferred Records	Increase (Decrease)	Percent Increase (Decrease)
ASBESTOS	571	270	14	295	(1)	3	562	3	(9)	-2%
PAXIL-BIRTH DEFECT	1	0	0	0	0	0	1	0	0	0%
FIREFIGHTER HEARING LOSS	1	0	0	0	0	0	1	0	0	0%
PHEN-FEN	2	0	0	1	0	0	1	0	(1)	-50%
YAZ/YAZMIN/OCELLA LITIGATION	3	0	0	2	0	0	1	0	(2)	-67%
RISPERDAL	6,543	926	5	596	31	3	6,912	218	369	6%
XARELTO	1,972	101	0	95	0	0	1,978	0	6	0%
PELVIC MESH LITIGATION	88	40	18	65	0	0	81	0	(7)	-8%
REGLAN LITIGATION	97	0	3	48	0	0	52	1	(45)	-46%
TOPAMAX LITIGATION	0	4	0	0	0	(4)	0	0	0	0%
ESSURE	0	229	0	0	0	59	288	0	288	0%
VENA CAVA FILTER	438	402	0	7	0	9	842	222	404	92%
TOTAL	9,716	1,972	40	1,109	30	70	10,719	444	1,003	10%


YTD DECEMBER TERM 2019: TIME TO DISPOSITION
MASS TORT PROGRAM DISPOSITION YTD TOTAL: 1,109



YTD DECEMBER TERM 2018: TIME TO DISPOSITION
MASS TORT PROGRAM DISPOSITION YTD TOTAL: 2,903



YTD DECEMBER TERM 2017: TIME TO DISPOSITION
MASS TORT PROGRAM DISPOSITION YTD TOTAL: 806




As defined by CourTools, Time to Disposition is an acknowledged measure of comparison, measured as the time it takes to process a case, from filing to disposition. A time standard is expressed in terms of the percentage of cases that should be resolved within a certain time frame. Courts should take note of existing guidelines and rules of court in their own jurisdiction when developing their own guidelines for each case type.


ABA Case Processing Standards

- * 90% within 12 months
- * 98% within 18 months
- * 100% within 24 months


YTD DECEMBER TERM 2019: TIME TO DISPOSITION ASBESTOS PROGRAM DISPOSITION TOTAL: 295



YTD DECEMBER TERM 2018: TIME TO DISPOSITION ASBESTOS PROGRAM DISPOSITION TOTAL: 286



YTD DECEMBER TERM 2017: TIME TO DISPOSITION ASBESTOS PROGRAM DISPOSITION TOTAL: 313




As defined by CourTools, Time to Disposition is an acknowledged measure of comparison, measured as the time it takes to process a case, from filing to disposition. A time standard is expressed in terms of the percentage of cases that should be resolved within a certain time frame. Courts should take note of existing guidelines and rules of court in their own jurisdiction when developing their own guidelines for each case type.


ABA Case Processing Standards

- * 90% within 12 months
- * 98% within 18 months
- * 100% within 24 months


YTD DECEMBER TERM 2019: TIME TO DISPOSITION PHARMACEUTICAL DISPOSITION TOTAL: 814



YTD DECEMBER TERM 2018: TIME TO DISPOSITION PHARMACEUTICAL DISPOSITION TOTAL: 2,617




YTD DECEMBER TERM 2017: TIME TO DISPOSITION PHARMACEUTICAL DISPOSITION TOTAL: 493




As defined by CourTools, Time to Disposition is an acknowledged measure of comparison, measured as the time it takes to process a case, from filing to disposition. A time standard is expressed in terms of the percentage of cases that should be resolved within a certain time frame. Courts should take note of existing guidelines and rules of court in their own jurisdiction when developing their own guidelines for each case type.

ABA Case Processing Standards

- * 90% within 12 months
- * 98% within 18 months
- * 100% within 24 months




Program Year	Asbestos Filings	Asbestos: Out of State Plaintiffs	Asbestos: % Out of State Plaintiffs	Program Year	Pharmaceutical Filings	Pharmaceuticals: Out of State Plaintiffs	Pharmaceuticals: % Out of State Plaintiffs
2010	284	106	37%	2010	2,305	2,060	89%
2011	312	147	47%	2011	2,435	2,132	88%
2012	327	143	44%	2012	489	420	86%
2013	330	109	33%	2013	483	429	89%
2014	268	90	34%	2014	1,827	1,617	89%
2015	258	84	33%	2015	1,030	830	81%
2016	286	99	35%	2016	1,329	990	74%
2017	287	134	47%	2017	5,118	4,599	90%
2018	258	154	60%	2018	1,336	1,146	86%
2019	270	121	45%	2019	1,702	1,447	85%




Program Year	Asbestos Filings	Asbestos: Out of State Plaintiffs	Asbestos: % Out of State Plaintiffs	Program Year	Pharmaceutical Filings	Pharmaceuticals: Out of State Plaintiffs	Pharmaceuticals: % Out of State Plaintiffs
2010	284	106	37%	2010	2,305	2,060	89%
2011	312	147	47%	2011	2,435	2,132	88%
2012	327	143	44%	2012	489	420	86%
2013	330	109	33%	2013	483	429	89%
2014	268	90	34%	2014	1,827	1,617	89%
2015	258	84	33%	2015	1,030	830	81%
2016	286	99	35%	2016	1,329	990	74%
2017	287	134	47%	2017	5,118	4,599	90%
2018	258	154	60%	2018	1,336	1,146	86%
2019	270	121	45%	2019	1,702	1,447	85%

Mass Tort Filings 2010 - 2019



MASS TORT FILINGS: 2016 - 2019 BREAKDOWN BY PROGRAM


2019 Total Filings: 1,972



Percentage Breakdown

- 2019 Risperdal Filings: 926 (47%)
- 2019 Vena Cava Filter Filings: 402 (20%)
- 2019 Asbestos Filings: 270 (14%)
- 2019 Essure Filings: 229 (12%)
- 2019 Remaining Pharmaceutical Filings: 145 (7%)

2018 Total Filings: 1,594



Percentage Breakdown

- 2018 Risperdal Filings: 681 (43%)
- 2018 Xarelto Filings: 435 (27%)
- 2018 Asbestos Filings: 258 (16%)
- 2018 Remaining Pharmaceutical Filings: 220 (14%)

2017 Total Filings: 5,405



Percentage Breakdown

- 2017 Risperdal Filings: 4,403 (81%)
- 2017 Xarelto Filings: 454 (8%)
- 2017 Asbestos Filings: 287 (5%)
- 2017 Remaining Pharmaceutical Filings: 261 (5%)

2016 Total Filings: 1,615



Percentage Breakdown

- 2016 Risperdal Filings: 620 (38%)
- 2016 Xarelto Filings: 691 (43%)
- 2016 Asbestos Filings: 286 (18%)
- 2016 Remaining Pharmaceutical Filings: 18 (1%)